Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of anti-thrombotic therapies in Chilean patients with non-valvular AF...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2017
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000800963 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872017000800963 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720170008009632017-11-27Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en ChileCorbalán,RamónConejeros,CarlosRey,CarlosStockins,BenjamínEggers,GermánAstudillo,CarlosLanas,FernandoPotthoff,SergioHouzvic,CésarMontecinos,HumbertoCharme,GustavoBugueño,ClaudioAguilar,JuanArriagada,GermánMarín,PatricioLarico,Martín Anticoagulants Atrial Fibrillation Chile Prognosis Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of anti-thrombotic therapies in Chilean patients with non-valvular AF. Aim: To describe the characteristics and 1-year outcomes of patients with recently diagnosed AF recruited in Chile into the prospective global GARFIELD-AF registry. Material and Methods: Between 2011-2016, we prospectively registered information of 971 patients recruited at 15 centers, 85% of them from the public system and 15% from the private sector. Demographics, clinical characteristics and use of antithrombotic therapies were recorded for all patients. Adverse clinical outcomes were analyzed in 711 patients with 1-year follow-up. Results: The mean age was 71.5 years (66-79), 50% were men. Mean CHAD2S2 Vasc and HAS BLED scores for stroke risk were 3.3 (2.0-4.0) and 1.5 (1.0-2.0) respectively. Oral anticoagulants were prescribed in 82% of patients. Seventy percent received Vitamin K antagonists, 10% novel direct anticoagulants or antiplatelet therapy and only 8% did not receive any antithrombotic therapy. Mean time in optimal therapeutic range (an international normalized ratio of 2 to 3), was achieved in only 40.7% (23.0-54.8) of patients receiving Vitamin K antagonists. One year rates of death, stroke/systemic embolism and bleeding were 4.75 (3.36-6.71), 2.40 (1.47-3.92) and 1.64% (0.91-2.97) per 100 person-years. Ischemic stroke occurred in 1.8% and hemorrhagic stroke in 0.8% of patients at 1-year of follow up. Conclusions: Although the use of vitamin K antagonists at baseline was high, the mean time in optimal therapeutic range was low. Mortality and stroke rates are higher than those reported in other contemporary registries.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.145 n.8 20172017-08-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000800963es10.4067/s0034-98872017000800963 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Anticoagulants Atrial Fibrillation Chile Prognosis |
| spellingShingle |
Anticoagulants Atrial Fibrillation Chile Prognosis Corbalán,Ramón Conejeros,Carlos Rey,Carlos Stockins,Benjamín Eggers,Germán Astudillo,Carlos Lanas,Fernando Potthoff,Sergio Houzvic,César Montecinos,Humberto Charme,Gustavo Bugueño,Claudio Aguilar,Juan Arriagada,Germán Marín,Patricio Larico,Martín Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile |
| description |
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with high rates of death, ischemic stroke and systemic embolism (SE). There is scarce information about clinical characteristics and use of anti-thrombotic therapies in Chilean patients with non-valvular AF. Aim: To describe the characteristics and 1-year outcomes of patients with recently diagnosed AF recruited in Chile into the prospective global GARFIELD-AF registry. Material and Methods: Between 2011-2016, we prospectively registered information of 971 patients recruited at 15 centers, 85% of them from the public system and 15% from the private sector. Demographics, clinical characteristics and use of antithrombotic therapies were recorded for all patients. Adverse clinical outcomes were analyzed in 711 patients with 1-year follow-up. Results: The mean age was 71.5 years (66-79), 50% were men. Mean CHAD2S2 Vasc and HAS BLED scores for stroke risk were 3.3 (2.0-4.0) and 1.5 (1.0-2.0) respectively. Oral anticoagulants were prescribed in 82% of patients. Seventy percent received Vitamin K antagonists, 10% novel direct anticoagulants or antiplatelet therapy and only 8% did not receive any antithrombotic therapy. Mean time in optimal therapeutic range (an international normalized ratio of 2 to 3), was achieved in only 40.7% (23.0-54.8) of patients receiving Vitamin K antagonists. One year rates of death, stroke/systemic embolism and bleeding were 4.75 (3.36-6.71), 2.40 (1.47-3.92) and 1.64% (0.91-2.97) per 100 person-years. Ischemic stroke occurred in 1.8% and hemorrhagic stroke in 0.8% of patients at 1-year of follow up. Conclusions: Although the use of vitamin K antagonists at baseline was high, the mean time in optimal therapeutic range was low. Mortality and stroke rates are higher than those reported in other contemporary registries. |
| author |
Corbalán,Ramón Conejeros,Carlos Rey,Carlos Stockins,Benjamín Eggers,Germán Astudillo,Carlos Lanas,Fernando Potthoff,Sergio Houzvic,César Montecinos,Humberto Charme,Gustavo Bugueño,Claudio Aguilar,Juan Arriagada,Germán Marín,Patricio Larico,Martín |
| author_facet |
Corbalán,Ramón Conejeros,Carlos Rey,Carlos Stockins,Benjamín Eggers,Germán Astudillo,Carlos Lanas,Fernando Potthoff,Sergio Houzvic,César Montecinos,Humberto Charme,Gustavo Bugueño,Claudio Aguilar,Juan Arriagada,Germán Marín,Patricio Larico,Martín |
| author_sort |
Corbalán,Ramón |
| title |
Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile |
| title_short |
Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile |
| title_full |
Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile |
| title_fullStr |
Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile |
| title_full_unstemmed |
Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile |
| title_sort |
características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con fa no valvular. lecciones del registro garfield af en chile |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2017 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000800963 |
| work_keys_str_mv |
AT corbalanramon caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT conejeroscarlos caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT reycarlos caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT stockinsbenjamin caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT eggersgerman caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT astudillocarlos caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT lanasfernando caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT potthoffsergio caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT houzviccesar caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT montecinoshumberto caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT charmegustavo caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT buguenoclaudio caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT aguilarjuan caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT arriagadagerman caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT marinpatricio caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile AT laricomartin caracteristicasbasalesmanejodeterapiasantitromboticasypronosticodepacienteschilenosconfanovalvularleccionesdelregistrogarfieldafenchile |
| _version_ |
1718436957971808256 |